The U.S. Food and Drug Administration has approved a new manufacturing facility for seasonal influenza vaccine production.
The facility, which is owned by Sanofi Pasteur, manufactures Fluzone Influenza Virus Vaccine, and could be used for the production of vaccines against the 2009 H1N1 influenza strain.
“Increased manufacturing capacity for influenza vaccine is critical to our preparedness for influenza pandemic,” said Jesse Goodman, the FDA’s acting chief scientist and deputy commission for scientific and medical programs. “This action also enhances the ability to produce and provide vaccines to protect the public from seasonal influenza.”
The bulk manufacturing facility will be used to produce Fluzone, an egg-based influenza vaccine. The company is headquartered in Swiftwater, Pa.